期刊
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
卷 39, 期 2, 页码 227-233出版社
WILEY-BLACKWELL
DOI: 10.1002/hed.24571
关键词
induction chemotherapy; response; organ preservation; T4 larynx; concomitant chemotherapy
资金
- Sanofi Aventis
Background. The optimal treatment for locally advanced laryngeal cancer remains controversial. The purpose of this trial was to determine if the response to induction chemotherapy could select patients for organ preservation protocols, and improve larynxpreservation rates without compromising overall survival (OS). Methods. The cohort comprised 12 patients with T3 disease and 14 with T4. Induction chemotherapy consisted of docetaxel, cisplatin, and 5fluorouracil (TPF). Response to the first cycle was determined by examination and positron emission tomography (PET)-CT. Responders (> 50% tumor reduction) underwent chemoradiation, whereas nonresponders underwent laryngectomy. Results. Eighty-three percent of the patients had a response and 17% had stable or progressive disease. At 2 years, the median OS was 80%, the larynx-preservation rate was 83%, and the disease-specific survival rate was 86%. Response to a single TPF cycle was associated with 2year OS (92% vs 50%; p =.02). The T classification was not predictive of survival. Conclusion. Response to a single TPF-based cycle may identify patients with advanced laryngeal cancer who are amenable to organ preservation treatment. (C) 2016 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据